NeuroOne Reports 72% Revenue Growth in Q2 Fiscal 2026 Despite Net Loss

NeuroOne Medical Technologies Corporation reported its financial results for the second quarter of fiscal 2026, revealing a product revenue of $2.4 million for the three months ended March 31, 2026, a significant increase of 72% compared to $1.4 million in the same period last year. For the six months ended March 31, 2026, total product revenue reached $5.3 million, up from $4.7 million in the prior year. Despite this growth, the company recorded a net loss of $2.1 million for the quarter, a slight improvement from a loss of $2.3 million in the previous year, and a total net loss of $3.5 million for the six months, compared to a loss of $0.5 million in the same period last year.

The company’s operational metrics indicate a focus on product development and commercialization, particularly with its OneRF Ablation Systems. The gross profit margin for the latest quarter was 53.8%, down from 55.6% in the prior year, attributed to increased component costs and a shift in sales mix. NeuroOne's total operating expenses for the quarter were $3.4 million, a decrease from $3.5 million in the previous year, reflecting cost management efforts in selling, general, and administrative expenses.

Strategically, NeuroOne has made significant advancements, including the completion of a limited market release of its OneRF TN Ablation System in March 2026. The company also entered into a securities purchase agreement in March 2026, raising $670,400 through the sale of 166,666 shares of common stock. Additionally, the company has been proactive in addressing its capital structure, having executed a reverse stock split in April 2026 to enhance its stock price and comply with Nasdaq listing requirements.

As of March 31, 2026, NeuroOne reported cash and cash equivalents of approximately $2.8 million, a decrease from $6.6 million at the end of the previous fiscal year. The company has expressed concerns regarding its ability to continue as a going concern, given its accumulated deficit of $82.1 million and ongoing operational losses. Management anticipates that additional funding will be necessary to support operations and product development, emphasizing the need for successful commercialization of its technologies to achieve profitability.

Looking ahead, NeuroOne remains focused on expanding its market presence and enhancing its product offerings. The company is optimistic about the potential for increased revenues from its distribution agreement with Zimmer, which grants exclusive rights to distribute its OneRF Ablation System. However, the company acknowledges the challenges posed by current economic conditions, including inflation and supply chain disruptions, which may impact its operational costs and access to capital in the future.